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Introduction
Gaucher disease is one of the most common hereditary
autosomal recessive sphingolipidoses. Caused by a
defect in lysosomal glucocerebrosidase,1 it is a
multisystem storage disorder manifested by anemia,
thrombocytopenia, hepatosplenomegaly, and bone
dysplasia. Primary involvement of the central nervous
system occurs in a minority of patients.2
Gaucher disease is divided into 3 subtypes, based on
the presence and progression of neurologic involvement.
Type 1 (non-neuronopathic) is the most common
subtype; it occurs at any age and has a heterogeneous
clinical presentation. Type 2 (acute neuronopathic) is
the most severe subtype and presents in the first month
of life. It has a rapidly progressive clinical course, with
The treatment of type 1 Gaucher disease has dramatically improved with the development of enzyme replacement
therapy (ERT). To date, however, imiglucerase treatment of this disease in Taiwanese pediatric patients has not
been reported. A Taiwanese child with type 1 Gaucher disease was regularly treated with imiglucerase beginning
October 1998. This 12-year 10-month-old boy had undergone splenectomy when he was 4 years old. He received
intravenous imiglucerase 60 U/kg every 2 weeks for 78 months. No signs of pubertal development were documented
at the commencement of ERT. There were no serious adverse effects. The patient had significant improvement in
skeletal deformity, a dramatic decrease in liver size, markedly increased linear growth, alleviation of bone pain and
bone crises, correction of anemia, and improved bone mineral density. ERT with imiglucerase improved the quality
of life in this child with type 1 Gaucher disease. [J Chin Med Assoc 2006;69(5):228–232]
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neurologic signs, including strabismus, trismus, and
spasticity. Type 3 (subacute neuronopathic) usually
occurs in childhood with a heterogeneous presentation;
neurologic signs develop by adolescence, often
beginning with a supranuclear gaze palsy.3
Type 1 Gaucher disease responds well to enzyme
replacement therapy (ERT) with recombinant
human macrophage-targeted recombinant human
glucocerebrosidase (imiglucerase, Cerezyme®;
Genzyme Corporation, Cambridge, MA, USA).4–7
This treatment was first introduced to Taiwan in
October 1998, but the results of therapy in Taiwanese
pediatric patients have not yet been reported. We have
evaluated the outcome of 6 years of treatment with
imiglucerase in a Taiwanese child with type I Gaucher
disease.
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Case Report
A boy born in December 1985 was first referred to
our outpatient department in August 1998 for
treatment of Gaucher disease. His parents were
nonconsanguineous and healthy. An elder brother
and elder sister had both died because of complications
of the disease. The child had undergone splenectomy
for severe splenomegaly at age 4 years. He fractured his
left knee at age 10 and his left hip at age 12. He also
had many episodes of bone crisis with severe bone
pain. He walked only with great difficulty and was
usually bedridden or wheelchair-bound. On physical
examination, his height was 128.5 cm (< 3rd percentile)
and weight was 25 kg (< 3rd percentile). He appeared
to have poor linear growth, and there were severe bone
deformities, multiple pathologic fractures, a barrel
chest, multiple joint contractures, and a valgus
deformity of the left knee joint. His extremities were
very thin and weak. There was arm- and leg-length
discrepancy (the right extremities being longer). He
had hepatomegaly, with a palpable liver edge 14 cm
below the subxiphoid process and 12 cm below the
right costal margin. The patient’s mental abilities were
normal, and he did not show any signs of puberty.
On admission, a lumbosacral spine radiograph
showed compression fractures of L1, L4, and L5.
Magnetic resonance imaging (MRI) of the pelvis and
lower extremities showed old infarcts in the lower
lumbar spine, the pelvic bones bilaterally, and the right
proximal and distal femur; avascular necrosis in both
femoral heads; and new infarcts in the right trochanter
and distal femur. Molecular analysis showed a
homozygous L444P mutation, based on polymerase
chain reaction (PCR)-restriction enzyme digestion
method.8 Laboratory investigations revealed the
following: leukocyte `-glucosidase, 0.39 μgmol/g
protein/hour (control, 2.7 μgmol/g protein/hour;
reference range, 1.0–5.0 μgmol/g protein/hour);
plasma chitotriosidase, 29,200 μgmol/hour (control,
47 μgmol/hour; reference range, 4–80 μgmol/ hour);
hemoglobin, 11.2 g/dL; platelet count, 257 × 109/L;
aspartate aminotransferase [AST], 72 U/L (normal
range, 5–45 U/L); alanine aminotransferase [ALT],
31 U/L (normal range, 5–45 U/L); acid phosphatase,
47.5 U/L (normal range, 0.11–0.60 U/L); and
alkaline phosphatase, 262 U/L (normal range, 200–
495 U/L).
The patient was given imiglucerase at a dose of
60 U/kg every other week beginning October 1998.
Imiglucerase came as a lyophilized powder and was
stored at 4°C until use, then diluted in 0.9% NaCl just
before infusion. It was infused intravenously through
a peripheral vein over 1–2 hours at a rate not exceeding
0.5–1 U/kg/min. The patient was weighed before
each infusion to adjust the dose. The annual cost of
this medication, approximately US$ 400,000 for a
40-kg patient, was covered by Taiwan’s National
Health Insurance. Assessment of response included
serial physical examination and laboratory tests,
including complete blood counts, liver function tests
(serum AST, ALT, and alkaline phosphatase), renal
function tests (blood urea nitrogen [BUN] and
creatinine), acid phosphatase, leukocyte ` -glucosidase,
and plasma chitotriosidase. Skeletal assessment included
plain radiographs of the femur, spine, and pelvis.
The patient responded well to ERT given over
78 months, at the end of which time he was 19 years,
4 months old. There were no serious adverse effects.
Puberty, beginning with pubic hair development, was
documented in March 2000, after ERT had been
implemented for 17 months. The patient had significant
improvement of his skeletal deformities, a tremendously
noticeable decrease in liver size, marked linear growth,
and markedly decreased bone pain and bone crises.
Figures 1A and B show the patient before and after
ERT. After treatment, he could lift his arms above his
shoulders without flexion. There was only a mild
residual chest cage deformity and mild kyphoscoliosis
and no palpable hepatosplenomegaly. After treatment,
the lumbar and sacral spine radiographs showed an
increased cortical thickness and no new compression
fractures.
On physical examination after 78 months of
treatment, the patient’s height was 156 cm and weight
was 41 kg. Figures 2A and B show the changes in
height and weight over the 6-year treatment course.
Table 1 shows serial hemoglobin concentrations,
platelet counts, liver and renal function tests, and acid
and alkaline phosphatase levels. The patient attained a
normal hemoglobin level 12 months after beginning
therapy. His platelet count was already within the
normal range before starting treatment because of the
splenectomy at age 4. However, the platelet count did
increase, particularly early in the course of therapy.
Because the patient received ERT before puberty, his
alkaline phosphatase was high during the first year but
then decreased gradually as he grew. The acid
phosphatase gradually decreased over the treatment
course.
We were only able to measure lumbar bone
mineral density (BMD) by dual-energy radiograph
absorptiometry after February 2001. The BMD of L2
to L4 was 0.645 g/cm2 at that time. However, BMD
gradually increased over the last 3 years of therapy,
with the latest data of 0.941 g/cm2 in July 2005.
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Figure 2. Change of the patient’s height (A) and weight (B) during 6 years of enzyme replacement therapy compared to normal height
and weight curves of Chinese children. Each closed circle represents one measurement of his height or weight.
Figure 1. The patient before and after enzyme replacement therapy (ERT). (A) Pre-ERT (12 years and 10 months old); (B) Post-ERT
(19 years and 4 months old).
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No new skeletal lesions occurred during treatment,
and the patient did not complain again of bone pain
after the first year of treatment. Because he had a 30–
40° genu valgum on the left, he underwent corrective
osteotomy of the left distal femur in April 2000. He
was able to walk well without crutches after surgery.
Figure 3 shows the effects of ERT on the plasma
chitotriosidase, a measurement thought to be an
indicator of response to ERT.9 It gradually decreased
over the course of treatment, and the comparison
between data at the beginning and the end of the study
shows a dramatic plummet. The liver was no longer
palpable below the right costal and subxiphoid margins
after ERT for 3 years.
Discussion
We have presented the first experience in Taiwan of
treating pediatric type 1 Gaucher disease with
imiglucerase. The only previous report of ERT for
type 1 Gaucher disease in Taiwan involved 6 adults.10
In those cases, ERT effectively reduced organomegaly,
corrected anemia and thrombocytopenia, improved
liver function, and alleviated bone pain. In our patient,
in addition to the above effects, imiglucerase also
enhanced linear growth, alleviated skeletal deformity,
and increased bone mineral density.
Gaucher disease severely impairs quality of life
because of hematologic or skeletal complications,
physical limitations, and psychosocial problems for
both patients and their families.11,12 In previous
studies, ERT has been shown to prevent progressive
manifestations of Gaucher disease, as well as
ameliorating specific features of the disease.4–6 Our
experience is consistent with these studies.
Improved linear growth is both medically and
socially important for children. In our patient, ERT
resulted in a marked acceleration of growth, increased
BMD, and alleviation of obvious skeletal deformities.
Our findings are consistent with those of previous
studies.13,14 Rosenthal et al7 concluded that ERT with
imiglucerase over 3.5 years produced objective reversal
of disease in both the axial and appendicular skeleton
in patients with Gaucher disease. They documented
marked improvement in marrow composition and
bone mass in both children and adults.
Deegan and Cox reported that  plasma
chitotriosidase decreased gradually after ERT, and
after 2 years of ERT, the chitotriosidase activity
decreased to 30% of the baseline value.15 Our findings
are similar to theirs. Moreover, our study showed
plasma chitotriosidase changed to the normal value
after ERT for 6 years.
The study by Weinreb et al found a 20–30%
decrease in liver volume within 1–2 years after beginning
ERT, with a reduction of 30–40% by 5 years.5 Our
patient suffered from hepatomegaly, with the liver
edge palpable 14 cm below the subxiphoid process
and 12 cm below the right costal margin before ERT;
Table 1. Serial hemoglobin concentrations, platelet counts, liver and renal function tests, and acid and alkaline phosphatase levels
Initial 12 mo 24 mo 36 mo 48 mo 60 mo 72 mo
Hemoglobin (g/dL) 11.2 13.4 13.5 13.2 13.1 13.4 13.6
Platelet count (x 103/μL) 257 697 505 519 515 417 324
AST (U/L) 72 33 27 25 26 25 41
ALT (U/L) 31 20 17 17 20 16 34
BUN (mg/dL) 13 6 8 7 10 12 9
Creatinine (mg/dL) 0.3 0.3 0.4 0.4 0.5 0.6 0.6
Alkaline phosphatase (U/L) 262 169 157 218 – 126 94
Acid phosphatase (U/L) 47.5 19.6 18 16.7 19.2 – 8
AST = serum aspartate aminotransferase; ALT = serum alanine aminotransferase; BUN = blood urea nitrogen.
Figure 3. The effects of enzyme replacement therapy on the
change of plasma chitotriosidase.
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however, after ERT for 3 years, the liver was no longer
palpable. Our experience is consistent with theirs.
In conclusion, our experience indicates that
imiglucerase therapy beginning before puberty can
significantly improve physical measures in type 1
Gaucher disease, with a marked enhancement in the
quality of life.
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